Trevor Leung

Trevor Leung

Auto-generated profile, based on publicly available information

Trevor Leung

Innovative Genomics Institute

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2025 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
AGAnna A. Griadunova
Anna A. Griadunova
NPNicholas L. Petrone
Nicholas L. Petrone
MMMadeleine Maker
Madeleine Maker
BPBrian Pallares
Brian Pallares
TLTrevor Leung
Trevor Leung
FWFang Wang
Fang Wang
Efflux pump-mediated multidrug resistance is a common mechanism by which cancer cells reduce the efficacy of a broad range of small-molecule therapeutics. We discovered that substituting the 4'-hydroxy group of doxorubicina known efflux pump substratewith an epi-amino group results in a new compound, doxorubamine, which exhibits substantially improved activity against drug-sensitive and -resistant cancer cells and organoids. Mechanistic studies reveal that doxorubamine is a poor substrate of P-glycoprotein, and it thus retains high potency against multidrug-resistant cancer. This synthetic modification provides a promising strategy for circumventing multidrug resistance beyond conventional approaches that rely on efflux pump inhibition.